Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis.

Farci P, Wollenberg K, Diaz G, Engle RE, Lai ME, Klenerman P, Purcell RH, Pybus OG, Alter HJ.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14562-7. doi: 10.1073/pnas.1210592109. Epub 2012 Jul 24.

2.

Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease.

Lirussi F, Beccarello A, Bortolato L, Morselli-Labate AM, Crovatto M, Ceselli S, Santini G, Crepaldi G.

Liver. 1999 Oct;19(5):381-8.

PMID:
10533795
3.

Natural history of hepatitis C and the impact of anti-viral therapy.

Boyer N, Marcellin P.

Forum (Genova). 2000 Jan-Mar;10(1):4-18. Review.

PMID:
10717254
4.

Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection.

Delladetsima JK, Boletis JN, Makris F, Psichogiou M, Kostakis A, Hatzakis A.

Liver Transpl Surg. 1999 Jul;5(4):294-300.

5.

Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection.

Zeremski M, Hooker G, Shu MA, Winkelstein E, Brown Q, Des Jarlais DC, Tobler LH, Rehermann B, Busch MP, Edlin BR, Talal AH.

J Hepatol. 2011 Sep;55(3):545-553. doi: 10.1016/j.jhep.2010.12.033. Epub 2011 Jan 21.

6.

Interferon treatment for chronic hepatitis C infection in hemophiliacs--influence of virus load, genotype, and liver pathology on response.

Hanley JP, Jarvis LM, Andrew J, Dennis R, Hayes PC, Piris J, Lee R, Simmonds P, Ludlam CA.

Blood. 1996 Mar 1;87(5):1704-9.

7.

Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment.

Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, Diquattro O, Di Marco V, Loiacono O, Volpes R, et al.

Hepatology. 1994 Feb;19(2):273-9.

PMID:
8294085
8.

Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.

Paraná R, Schinoni MI, de Freitas LA, Codes L, Cruz M, Andrade Z, Trepo C.

Liver Int. 2006 Nov;26(9):1148-54.

PMID:
17032416
9.

Clinical assessment and incidence of hepatitis C RNA in 50 consecutive RIBA-positive volunteer blood donors.

McCaughan GW, McGuinness PH, Bishop GA, Painter DM, Lien AS, Tulloch R, Wylie BR, Archer GT.

Med J Aust. 1992 Aug 17;157(4):231-3.

PMID:
1279365
10.

The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease.

Alter HJ, Nakatsuji Y, Melpolder J, Wages J, Wesley R, Shih JW, Kim JP.

N Engl J Med. 1997 Mar 13;336(11):747-54.

11.

Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection.

Hajarizadeh B, Lamoury FM, Feld JJ, Amin J, Keoshkerian E, Matthews GV, Hellard M, Dore GJ, Lloyd AR, Grebely J, Applegate TL; ATAHC Study Group.

Virol J. 2016 Feb 24;13:32. doi: 10.1186/s12985-016-0482-x.

12.

Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity.

Curran R, Jameson CL, Craggs JK, Grabowska AM, Thomson BJ, Robins A, Irving WL, Ball JK.

J Gen Virol. 2002 Jan;83(Pt 1):11-23.

PMID:
11752696
13.

Genotype diversity of hepatitis C virus (HCV) in HCV-associated liver disease patients in Indonesia.

Utama A, Tania NP, Dhenni R, Gani RA, Hasan I, Sanityoso A, Lelosutan SA, Martamala R, Lesmana LA, Sulaiman A, Tai S.

Liver Int. 2010 Sep;30(8):1152-60. doi: 10.1111/j.1478-3231.2010.02280.x. Epub 2010 May 21.

PMID:
20492518
14.

Association between histological findings, aminotransferase levels and viral genotype in chronic hepatitis C infection.

Fecury AA, Almeida MK, Santos KN, Freitas Ada S, Dantas Sde F, Costa CA, Crescente ÂB, Sousa RC, Brito EB, Nassiri R, Lampe E, Martins LC.

Rev Soc Bras Med Trop. 2014 Jan-Feb;47(1):90-2.

15.

A rapid chemokine response of macrophage inflammatory protein (MIP)-1α, MIP-1β and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C.

Florholmen J, Kristiansen MG, Steigen SE, Sørbye SW, Paulssen EJ, Kvamme JM, Konopski Z, Gutteberg T, Goll R.

Clin Microbiol Infect. 2011 Feb;17(2):204-9. doi: 10.1111/j.1469-0691.2010.03206.x.

16.

Delayed induction, not impaired recruitment, of specific CD8⁺ T cells causes the late onset of acute hepatitis C.

Shin EC, Park SH, Demino M, Nascimbeni M, Mihalik K, Major M, Veerapu NS, Heller T, Feinstone SM, Rice CM, Rehermann B.

Gastroenterology. 2011 Aug;141(2):686-95, 695.e1. doi: 10.1053/j.gastro.2011.05.006. Epub 2011 May 18.

17.

Effect of anti-viral therapy for occult hepatitis C virus infection.

Pardo M, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Perez-Mota A, Carreño V.

Aliment Pharmacol Ther. 2006 Apr 15;23(8):1153-9.

18.

Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee.

Yi M, Hu F, Joyce M, Saxena V, Welsch C, Chavez D, Guerra B, Yamane D, Veselenak R, Pyles R, Walker CM, Tyrrell L, Bourne N, Lanford RE, Lemon SM.

J Virol. 2014 Apr;88(7):3678-94. doi: 10.1128/JVI.03540-13. Epub 2014 Jan 15.

19.

Recurrence of hepatitis C virus (genotype 4) infection after living-donor liver transplant in Egyptian patients.

Yosry A, Abdel-Rahman M, Esmat G, El-Serafy M, Omar A, Doss W, Zayed N, Said M, Ismail T, Hosny A, Marawan E, El-Malt O, Kamel RR, Hatata Y, El-Taweel A, Ghali A, Sabri H, Kamel S, El-Gabaly H.

Exp Clin Transplant. 2009 Sep;7(3):157-63.

20.

Prospective study of a high-intensity interferon-alpha regimen for chronic hepatitis C virus genotype 1b infection.

Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Tanikawa M, Sone Y, Hisanaga Y, Hayashi K.

Hepatogastroenterology. 2002 Nov-Dec;49(48):1619-24.

PMID:
12397749

Supplemental Content

Support Center